Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04869449 · ClinicalTrials.gov registry record · Early Phase 1

Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas

A Early Phase 1 study, sponsored by Milton S. Hershey Medical Center.

Terminated
Registry status
Early Phase 1
Development phase
1
Enrollment target

NCT04869449 is a Early Phase 1 study that was terminated before completion, run by Milton S. Hershey Medical Center. The registered enrollment target is 1 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04869449, a Early Phase 1 study, was terminated before completion, sponsored by Milton S. Hershey Medical Center.

TERMINATED
Registry status
Early Phase 1
Development phase
1 participants
Enrollment target

Study Summary

This research is being done to find out if the study drug (ketoconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Ketoconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. As treatments for this type of brain tumor are limited, it is hoped that the results of this study will help to determine if the study drug should be studied further as a possible treatment.

Interventions

  • DRUG Ketoconazole

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2022-05-11
Est. Completion 2022-05-12
Phase Early Phase 1

Sponsor

Milton S. Hershey Medical Center

396 total trials

What the Registry Record Tells You About NCT04869449

The ClinicalTrials.gov registry entry for NCT04869449 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Ketoconazole is the first listed.

NCT04869449 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04869449 about?

NCT04869449 is a clinical study titled "Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas". This research is being done to find out if the study drug (ketoconazole) can enter brain tumors at a high enough amount to stop the tumor cells from dividing. Ketoconazole is a drug which doctors already use for fungal infections and is thought to be able to effect tumor cells. As treatments for thi...

What is the current status of trial NCT04869449?

This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 1 participants. The study started on 2022-05-11. Estimated completion is 2022-05-12.

What interventions are being tested in trial NCT04869449?

The interventions under investigation include: Ketoconazole (DRUG).

Who is sponsoring clinical trial NCT04869449?

This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.